Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BTMDNASDAQ:DERMOTCMKTS:HSTCNASDAQ:NVCT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBTMDbiote$3.67+3.7%$3.57$3.04▼$8.44$193.67M1.16191,447 shs103,137 shsDERMJourney Medical$7.54+1.2%$6.89$3.54▼$8.25$175.65M0.8684,528 shs72,231 shsHSTCHST Global$0.83$0.79$0.23▼$1.11$47.95M-1.191,185 shsN/ANVCTNuvectis Pharma$8.97+1.2%$9.31$4.44▼$11.80$187.42M-0.16128,631 shs50,477 shs10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBTMDbiote+3.67%+1.94%+8.58%-13.85%-45.14%DERMJourney Medical+1.21%-6.57%+15.03%+46.69%+69.44%HSTCHST Global0.00%0.00%0.00%+23.87%-15.31%NVCTNuvectis Pharma+1.24%-4.06%+0.11%+29.44%+47.29%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBTMDbiote3.2458 of 5 stars3.55.00.00.00.03.31.3DERMJourney Medical2.2393 of 5 stars3.64.00.00.00.01.70.6HSTCHST GlobalN/AN/AN/AN/AN/AN/AN/AN/ANVCTNuvectis Pharma2.1208 of 5 stars3.50.00.00.00.65.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBTMDbiote 3.00Buy$8.00117.98% UpsideDERMJourney Medical 3.20Buy$9.8830.97% UpsideHSTCHST Global 0.00N/AN/AN/ANVCTNuvectis Pharma 3.00Buy$17.0089.52% UpsideCurrent Analyst Ratings BreakdownLatest HSTC, NVCT, BTMD, and DERM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/15/2025DERMJourney MedicalAlliance Global PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy4/30/2025NVCTNuvectis PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$11.00 ➝ $15.004/2/2025NVCTNuvectis PharmaMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$17.003/27/2025DERMJourney MedicalIndustrial Alliance SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$10.503/27/2025DERMJourney MedicalAlliance Global PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy3/17/2025NVCTNuvectis PharmaLaidlawSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$19.003/13/2025BTMDbioteCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$12.00 ➝ $8.00(Data available from 6/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBTMDbiote$199.38M1.01$0.38 per share9.60($0.58) per share-6.33DERMJourney Medical$56.24M3.12$0.27 per share28.37$1.05 per share7.18HSTCHST GlobalN/AN/AN/AN/AN/AN/ANVCTNuvectis PharmaN/AN/AN/AN/A$0.70 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBTMDbiote$3.32M$0.6114.126.80N/A5.20%-32.41%22.26%8/14/2025 (Estimated)DERMJourney Medical-$3.85M-$0.39N/AN/AN/A-31.74%-132.10%-26.90%8/11/2025 (Estimated)HSTCHST Global-$150K-$0.02N/A∞N/AN/A-13,072.91%-31.66%N/ANVCTNuvectis Pharma-$22.26M-$1.13N/AN/AN/AN/A-155.80%-104.02%8/5/2025 (Estimated)Latest HSTC, NVCT, BTMD, and DERM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025DERMJourney Medical-$0.24-$0.18+$0.06-$0.18$12.05 million$13.14 million5/7/2025Q1 2025BTMDbiote$0.06$0.08+$0.02$0.37$47.25 million$48.99 million5/6/2025Q1 2025NVCTNuvectis Pharma-$0.30-$0.27+$0.03-$0.27N/AN/A3/26/2025Q4 2024DERMJourney Medical-$0.22$0.08+$0.30$0.08$14.21 million$14.30 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBTMDbioteN/AN/AN/AN/AN/ADERMJourney MedicalN/AN/AN/AN/AN/AHSTCHST GlobalN/AN/AN/AN/AN/ANVCTNuvectis PharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBTMDbioteN/A1.501.16DERMJourney Medical1.811.381.03HSTCHST GlobalN/A0.250.25NVCTNuvectis PharmaN/A2.742.74Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBTMDbiote21.68%DERMJourney Medical7.25%HSTCHST GlobalN/ANVCTNuvectis Pharma96.77%Insider OwnershipCompanyInsider OwnershipBTMDbiote24.00%DERMJourney Medical15.03%HSTCHST Global65.82%NVCTNuvectis Pharma30.52%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBTMDbiote19454.71 million46.78 millionNot OptionableDERMJourney Medical9023.30 million18.14 millionN/AHSTCHST Global157.77 million16.33 millionNot OptionableNVCTNuvectis Pharma820.89 million12.41 millionNot OptionableHSTC, NVCT, BTMD, and DERM HeadlinesRecent News About These CompaniesNuvectis Pharma to Present at the H.C. Wainwright BioConnect Investor ConferenceMay 16, 2025 | globenewswire.comNuvectis Pharma, Inc. (NASDAQ:NVCT) Major Shareholder Marlio Charles Mosseri Buys 21,167 SharesMay 14, 2025 | insidertrades.comHC Wainwright Predicts Stronger Earnings for Nuvectis PharmaMay 11, 2025 | marketbeat.comQ2 EPS Estimates for Nuvectis Pharma Lifted by Roth CapitalMay 11, 2025 | marketbeat.comInsider Buying: Nuvectis Pharma, Inc. (NASDAQ:NVCT) Major Shareholder Purchases 2,650 Shares of StockMay 10, 2025 | insidertrades.comDoes Nuvectis Pharma (NVCT) Have the Potential to Rally 108.79% as Wall Street Analysts Expect?May 9, 2025 | zacks.comNuvectis Pharma (NASDAQ:NVCT) Is In A Good Position To Deliver On Growth PlansMay 9, 2025 | finance.yahoo.comNuvectis Pharma (NASDAQ:NVCT) Issues Earnings ResultsMay 8, 2025 | marketbeat.comNuvectis Pharma, Inc. Reports First Quarter 2025 Financial Results and Business Highlights | ...May 6, 2025 | gurufocus.comNuvectis Pharma, Inc. Reports First Quarter 2025 Financial Results and Business HighlightsMay 6, 2025 | gurufocus.comNuvectis Pharma, Inc. Reports Promising Phase 1a Data for NXP900 and Secures $15.5 Million FinancingMay 6, 2025 | quiverquant.comNuvectis Pharma, Inc. Reports First Quarter 2025 Financial Results and Business HighlightsMay 6, 2025 | globenewswire.comNuvectis Pharma, Inc. Announces Positive Phase 1a Data for NXP900 Demonstrating Robust Pharmacodynamic Responses and Acceptable Safety ProfileMay 1, 2025 | nasdaq.comWhy Nuvectis Pharma, Inc.’s (NVCT) Stock Is Down 5.45%April 30, 2025 | aaii.comWhy Nuvectis Pharma, Inc. (NVCT) is Surging in 2025April 30, 2025 | insidermonkey.comNuvectis Pharma Provides Poster Presentation Highlights for NXP900 from the 2025 AACR MeetingApril 29, 2025 | globenewswire.comMaxim Group Initiates Coverage of Nuvectis Pharma (NVCT) with Buy RecommendationApril 3, 2025 | msn.comNuvectis Pharma initiated with a Buy at MaximApril 3, 2025 | markets.businessinsider.comNuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2025 American Association for Cancer Research MeetingMarch 26, 2025 | markets.businessinsider.comWhy Nuvectis Pharma, Inc.’s (NVCT) Stock Is Down 11.52%March 26, 2025 | aaii.comLaidlaw & Co. Initiates Coverage of Nuvectis Pharma (NVCT) with Buy RecommendationMarch 18, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeHSTC, NVCT, BTMD, and DERM Company Descriptionsbiote NASDAQ:BTMD$3.67 +0.13 (+3.67%) Closing price 06/5/2025 04:00 PM EasternExtended Trading$3.73 +0.06 (+1.63%) As of 06/5/2025 05:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support. It also sells dietary supplements under the Biote brand; and sterile pellet insertion kits that is used with hormone optimization therapies for male and female. The company was founded in 2012 and is headquartered in Irving, Texas.Journey Medical NASDAQ:DERM$7.54 +0.09 (+1.21%) Closing price 06/5/2025 04:00 PM EasternExtended Trading$7.41 -0.13 (-1.78%) As of 06/5/2025 04:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also offers Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Exelderm cream and solution an antifungal intended for topical use; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; and Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. In addition, the company sells sulconazole nitrate cream and solution indicated for the treatment of tinea cruris, tinea corporis, and tinea versicolor; and doxycycline hyclate tablets, as an adjunctive therapy for severe acne. The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona. Journey Medical Corporation is a subsidiary of Fortress Biotech, Inc.HST Global OTCMKTS:HSTC$0.83 0.00 (0.00%) As of 06/4/2025HST Global, Inc., operates as an integrated health and wellness biotechnology company in the United States. The company develops and/or acquires a network of wellness centers for the homeopathic and alternative treatment of late stage cancer and other life threatening diseases. It also focuses on the homeopathic and alternative product candidates that are undergoing or have already completed clinical testing for the treatment of late stage cancer and or/ life threatening diseases. HST Global, Inc. is headquartered in Hampton, Virginia.Nuvectis Pharma NASDAQ:NVCT$8.97 +0.11 (+1.24%) Closing price 06/5/2025 04:00 PM EasternExtended Trading$8.93 -0.04 (-0.45%) As of 06/5/2025 05:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma. It is also developing NXP900, a small molecule drug candidate, which is in Phase 1a clinical trails that inhibits the Proto-oncogene c-Src and YES1 kinases. It has license agreement with the CRT Pioneer Fund for the NXP800 and any of related derivatives; and the University of Edinburgh for the NXP900 and any of associated derivatives. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas AT&T: Is This Telecom Giant a Buy or a Bye for Your Portfolio? Is Meta Plotting a Stablecoin Comeback Years After Libra's Flop? NVIDIA Regains Top Spot; FOMO Is Why It Will Continue to Rise Robinhood Stock Keeps Giving Investors Reasons To Buy Hims & Hers Stock: Buy the Dip or Wait It Out? Boeing: Analyst Upgrades & Order Boom Signal Clearer Skies CrowdStrike Stock Dips on Guidance Miss: It May Rebound Fast A New All-Time High Is Coming Soon for Credo Technology Group Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
